Change Password!
Reset Password!
A novel
generation platelet-rich fibrin appears to be suitable to treat periodontal
defects.
For surgical therapy of intrabony periodontal defects, the novel-generation platelet-rich fibrin exhibited similar clinical effectiveness as enamel matrix derivative (EMD), according to a randomized, controlled, prospective clinical trial published in BMC Oral Health. Investigators undertook this study to compare the healing efficacy of intrabony defects following therapy with a novel generation platelet-rich fibrin (A-PRF+) and EMD.
Overall, 30 intrabony defects of eighteen people (9 men, 9 women) were randomly managed with A-PRF+ (test, n = 15) or EMD (control, n = 15). At the baseline and six months following surgery, recording of the clinical parameters such as probing depth, gingival recession, clinical attachment level, and bone sounding was done.
Following debridement, the intrabony defects were filled with either A-PRF+ or EMD. This was followed by fixation using sutures for ensuring wound stability and closure. Compared to baseline, a considerable improvement was noted in the outcomes assessed after six months. However, both methodologies led to similar outcomes. No profound differences were reported between A-PRF+ and EMD groups, as shown in Table 1:
Management with A-PRF+ or EMD led to reliable clinical outcomes. Thus, the usage of new-generation platelet-rich fibrin as a human autologous product appears to positively influence periodontal healing and regeneration.
BMC Oral Health
Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
Boróka Klára Csifó-Nagy et al.
Comments (0)